[第一个患有扩散性大B细胞淋巴瘤的意大利患者,在第二行用轴细胞治疗:创新和传统]
Stefania Bramanti1, Davide Chizzoniti1, Daniele Mannina1
1Terapia Cellulare e CAR -T, Humanitas Cancer Center, Rozzano (Milano).
Recenti progressi in medicina
|February 11, 2025
概括
化学抗原受体T细胞 (CAR-T) 疗法为分散型大B细胞淋巴瘤 (DLBCL) 患者提供了一种新的治疗方法,这些患者对初始疗法没有反应. 早期识别预后因素可以确保符合条件的患者及时获得这种先进的CAR-T细胞疗法.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 仍然具有挑战性,特别是初级化学抵抗.
- 目前的治疗方法包括抗CD20单克隆抗体,但对抗化学性病例的结果不佳.
- 化学抗原受体T细胞 (CAR-T) 疗法已成为一个显著的进步.
研究的目的:
- 突出CAR-T细胞治疗对耐火性/复发性DLBCL的影响.
- 强调早期识别DLBCL的预后因素的必要性.
- 为方便适合患者及时获得CAR-T疗法.
主要方法:
- 审查CAR-T细胞治疗在DLBCL治疗中的作用.
- 对DLBCL临床表现的预后因素的分析.
- 讨论化学耐药DLBCL的治疗途径.
主要成果:
- 在复发/耐药病例中,CAR-T细胞疗法在12个月内改变了DLBCL治疗.
- 它提供了高剂量化疗和干细胞再输注的替代方案.
- 早期预后因素的识别对于治疗选择至关重要.
结论:
- 卡尔-T细胞疗法是针对特定DLBCL群体的革命性治疗方法.
- 确定预后因素是优化患者选择CAR-T治疗的关键.
- 综合方法确保符合条件的DLBCL患者能够快速获得CAR-T疗法.
相关概念视频
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
